Rhode Island Senate Bill S2070

Rhode Island 2022 Regular Session

• Introduced: 1/25/22
• Refer: 1/25/22

Caption

Wholesale Prescription Drug Importation Program

Impact

The bill will require the designation of a state agency to serve as a licensed drug wholesaler or to partner with an existing licensed wholesaler. This agency will be responsible for implementing the program in a way that adheres to the restrictions and standards set by the FDA, including ensuring that only approved drugs expected to generate substantial cost savings are imported. Additionally, the distribution and sale of these imported drugs will be limited to within Rhode Island, thus preventing interstate commerce of these products.

Summary

S2070 establishes a Wholesale Prescription Drug Importation Program, allowing the state of Rhode Island to import prescription drugs from Canada to provide cost savings for its residents. The bill aims to create a structured program that complies with federal regulations, particularly ensuring safety and effectiveness of drugs being imported. The initiative is set against a backdrop of rising prescription drug costs in the United States, with the hope of relieving financial burdens on consumers through significant savings.

Contention

There may be notable points of contention regarding S2070, primarily around the regulatory hurdles of drug importation and the anticipated pushback from established pharmaceutical interests. Advocates argue that this program is essential for making healthcare more affordable, while opponents may raise concerns about the quality and safety of imported drugs, fearing potential complications in maintaining oversight. Furthermore, the detailed requirements for federal approval and ongoing consultations with various stakeholders might lead to delays in implementation or complications in compliance with federal regulations.